The therapeutic potential of targeting drugs at transcription factors

Bibliography

• SEMENZA GL: Gene expression and transcriptional regulation. In: Transcription Factors and Human Disease. Oxford University Press, New York, USA (1998):3–25.
   Google Scholar
• SEMENZA GL: Cis-acting transcriptional regulatory elements. In: Transcription Factors and Human Disease. Oxford University Press, New York, USA (1998):26–41.
   Google Scholar
• PAPAVASSILIOU AG: Transcription factors. New Engl. J Med. (1995) 332:45–47.
   PubMed Web of Science ®Google Scholar
• SEMENZA GL: Trans-acting factors. In: Transcription Factors and Human Disease. Oxford University Press, New York, USA (1998):42–110.
   Google Scholar
• OUZOUNIS CA, PAPAVASSILIOU AG: DNA-bindingmotifs of eukaryotic transcription factors. In: Transcription Factors in Eukaryotes. Papavassiliou AG (Ed.), Landes Bioscience, Austin, USA (1997):1–21.
   Google Scholar
• LATCHMAN DS: What regulates the regulators? In: Eukaiyotic Transcription Factors (3rd Edition). Academic Press, San Diego, USA (1998):323–359.
   Google Scholar
• TREIER M, BOHMANN D: Phosphorylation of transcrip-tion factors. In: Protein Phosphorylation. Marks F (Ed.), VCH Publishers, Weinheim, Germany (1996):297–327.
   Google Scholar
• MANGELSDORF DJ, THUMMEL C, BEATO M et al.: The nuclear receptor superfamily: the second decade. Cell (1995) 83:835–839.
   PubMed Web of Science ®Google Scholar
• GOTTLICHER M, RAHMSDORF HJ, HERRLICH P: The AP-1 family of transcription factors: multi-level control of activity. In: Transcription Factors in Eukalyotes. Papayas-siliou AG (Ed.), Landes Bioscience, Austin, USA (1997):67–93.
   Google Scholar
• BAEUERLE PA, BALTIMORE D: NF-KB ten years after. Cell (1996) 87:13–20.
   PubMed Web of Science ®Google Scholar
• LATCHMAN DS: How can we use our growing understanding of gene transcription to discover effective new medicines? Curr. Opin. Biotechnol. (1997) 8:713–717.
   PubMed Web of Science ®Google Scholar
• PAPAVASSILIOU AG: Transcription-factor-modulating agents: precision and selectivity in drug design. Mol Med. Today (1998) 4:358–366.
   PubMedGoogle Scholar
• •A recent review on the structure-function qualifications of transcription factors for rational drug targeting.
   Google Scholar
• CAI W, HU L, FOULKES JG: Transcription-modulating drugs: mechanism and selectivity. Curr. Opin. Biotechnol (1996) 7:608–615.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the currently used drugs that modulate transcription and their mechanism of action.
   Google Scholar
• SHAW KT-Y, HO AM, RAGHAVAN A et al.: Immunosup- pressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc. Natl. Acad. Sci. USA (1995) 92:11205–11209.
   PubMed Web of Science ®Google Scholar
• LUO C, SHAW KT-Y, RAGHAVAN A et al.: Interaction ofcalcineurin with a domain of the transcription factor NFAT1 that controls nuclear import. Proc. Natl. Acad. Sci. USA (1996) 93:8907–8912.
   PubMed Web of Science ®Google Scholar
• JAIN J, McCAFFEY PG, VALGE-ARCHER VE, RAO A: Nuclear factor of activated T cells contains Fos and Jun. Nature (1992) 356:801–804.
   PubMed Web of Science ®Google Scholar
• JAIN J, McCAFFEY PG, MINER Z et al.: The T-celltranscription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature (1993) 365:352–355.
   PubMed Web of Science ®Google Scholar
• FRANTZ B, NORDBY EC, BREN G et al: Calcineurin actsin synergy with PMA to inactivate IKB/MAD3, an inhibitor of NF-KB. EMBO J (1994) 13:861–870.
   PubMed Web of Science ®Google Scholar
• KIU J, FARMER JD, LANA WS, FRIEDMAN J, WEISSMAN I,SCHREIBER SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complex. Cell (1991) 66:807–815.
   PubMed Web of Science ®Google Scholar
• KAWAMURA A, SU MS-S: Interaction of FKBP12-FK506 with calcineurin A at the B subunit-binding protein. J. Biol. Chem. (1995) 270:15463–15466.
   PubMed Web of Science ®Google Scholar
• PARK J, YASEEN NR, HOGAN PG, RAO A, SHARMA S: Phosphorylation of the transcription factor NFATp inhibits its DNA binding activity in cyclosporin A-treated human B and T cells. J. Biol. Chem. (1995) 270:20653–20659.
   PubMed Web of Science ®Google Scholar
• WIEDERRECHT G. LAM E, HUNG S, MARTIN M, SIGAL N:The mechanism of action of FK506 and cyclosporin A. Ann. NY Acad. Sci. (1993) 696:9–19.
   PubMed Web of Science ®Google Scholar
• WANG DZ, McCAFFEY PG, RAO A: The cyclosporin-sensitive transcription factor NFATp is expressed in several classes of cells in the immune system. Ann. NY Acad. Sci. (1995) 766:182–194.
   PubMed Web of Science ®Google Scholar
• BROWN EJ, BEAL PA, KEITH CT, CHEN J, SHIN TB, SCHREIBER SL: Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature (1995) 377:441–446.
   PubMed Web of Science ®Google Scholar
• DEGROOT RP, BALLOU LM, SASSONE-CORSI P: Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell (1994) 78:81–91.
   Web of Science ®Google Scholar
• FEUERSTEIN N, HUANG D, PRYSTOWSKI MB: Rapamycinselectively blocks interleukin-2-induced proliferating nuclear antigen gene expression in T lymphocytes. J. Biol. Chem. (1995) 270:9454–9458.
   PubMed Web of Science ®Google Scholar
• EVANS RM: The steroid and thyroid hormone receptorsuperfamily. Science (1988) 240:889–895.
   PubMed Web of Science ®Google Scholar
• SCHOONJANS K, STAELS B, AUWERX J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of flbrates and fatty acids on gene expression. J. Lipid Res. (1996) 37:907–925.
   PubMed Web of Science ®Google Scholar
• SCHOONJANS K, MARTIN G, STAELS B, AUWERX J: Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. (1997) 8:159–166.
   PubMed Web of Science ®Google Scholar
• TABOUL L, GSILLARD D, STACCINI L, INADERA H, AMRIEZ, GRIMALDI PA: Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J. Biol. Chem. (1995) 270:28183–28187.
   PubMed Web of Science ®Google Scholar
• SZALKOWSKE D, WHITE-CARRINGTON S, BERGER J, ZHANG B: Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-a on differ-entiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology (1995) 136:1474–1481.
   PubMed Web of Science ®Google Scholar
• OHAUMI J, SAKAKIBARA S, YAMAGUCHI J et al.: Troglita-zone prevents the inhibitory effect of inflammatory cytokines on insulin-induced adipose differentiation in 3T3-L1 cells. Endocrinology (1994) 135:2279–2282.
   PubMed Web of Science ®Google Scholar
• KURTZ TW, GARDNER DG: Transcription-modulating drugs. A new frontier in the treatment of essential hypertension. Hypertension (1998) 32:380–386.
   PubMed Web of Science ®Google Scholar
• LAW RE, MEEHAN WP, XI XP et al.: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. j Clin. Invest. (1996) 98:1897–1905.
   PubMed Web of Science ®Google Scholar
• MORIKANG E, BENSON SC, KURTZ TW, PERSHADSINGH HA: Effects of thiazolidinediones on growth and differ-entiation of human aorta and coronary myocytes. Am. Hypertens. (1997) 10:440–446.
   PubMed Web of Science ®Google Scholar
• GRAF K, XI XP, HSUEH WA, LAW RE: Troglitazone inhibits angiotensin ffinduced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett. (1997) 400:119–121.
   PubMed Web of Science ®Google Scholar
• ALTIOK S, XU M, SPIEGELMAN BM: PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. (1997) 11:1987–1998.
   PubMed Web of Science ®Google Scholar
• WU DA, BU X, WARDEN CH et al.: Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22. j Clin. Invest. (1996) 97:2111–2118.
   PubMed Web of Science ®Google Scholar
• AITMAN TJ, GOTODA T, EVANS AL et al.: Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nature Genet. (1997) 16:197–201.
   PubMed Web of Science ®Google Scholar
• BOTTGER A, VAN LITH HA, KREN V et al. Quantitative trait loci influencing cholesterol and phospholipid phenotypes map to chromosomes that contain genes regulating blood pressure in the spontaneously hypertensive rat. J. Clin. Invest. (1996) 98:856–862.
   PubMed Web of Science ®Google Scholar
• GRONEMEYER H: Transcription activation by estrogen and progesterone receptors. Ann. Rev. Genet. (1991) 25:89–123.
   PubMed Web of Science ®Google Scholar
• NOGUCHI S, MOTOMURA K, INAJI H, IMAOKA S, KOYAMA H: Down-regulation of transforming growth factor-a by tamoxifen in human breast cancer. Cancer (1993) 72:131–136.
   PubMed Web of Science ®Google Scholar
• HUYNTH HT, POLLAK M: Insulin-like growth factor-1 gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res. (1993) 53:5585–5588.
   PubMed Web of Science ®Google Scholar
• YANG NN, BRYAN HU, HARDIKAR S et al.: Estrogen and raloxifene stimulate transforming growth factor-I33 gene expression in rat bone: potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology (1996) 137:2075–2084.
   PubMed Web of Science ®Google Scholar
• TUMER CH, SATO M, BRYANT HU: Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology (1994) 135:2001–2005.
   PubMed Web of Science ®Google Scholar
• DRAPER MW, FLOWERA DE, HUETER WJ, NEIDL JA, HARPER KD, ARNAUD C: A controlled trial of raloxifene (LY 139481)HCL: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. (1996) 11:835–842.
   PubMed Web of Science ®Google Scholar
• KOPP E, GHOSH S: Inhibition of NF-KB by sodium salicylate and aspirin. Science (1994) 265:956–959.
   PubMed Web of Science ®Google Scholar
• PIERCE JW, READ MA, DING H, LUSCINSKAS FW, COLLINS T: Salicylates inhibit IKB-a phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. (1996) 156:3961–3969.
   PubMed Web of Science ®Google Scholar
• HUDSON N, WAWTHRONE AB, COLE AT, JONES PD, HAWKEY CJ: Mechanisms of gastric and duodenal damage and protection. Hepatogastroenterology (1992) 39\(Suppl. 1)31–36.
   Google Scholar
• SCHRECK R, KISTLER B, WIRTH T: The NF-x13/Rel system of transcriptional activators. In: Transcription Factors in Eukaryotes. Papavassiliou AG (Ed.), Landes, Bioscience, Austin, USA (1997):153–188.
   Google Scholar
• MULLER CW, REY FA, SODEOKA M et al.: Structure of the NF-KB p50 homodimer bound to DNA. Nature (1995) 373:311–317.
   PubMed Web of Science ®Google Scholar
• BEG AA, RUBEN SM, SCHEINMAN RI, HASKILL S, ROSEN CA, BALDWIN AS, JR.: I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev. (1992) 6:1899–1913.
   Google Scholar
• HURST HC: Transcription factors as drug targets in cancer. Eur. J. Cancer (1996) 32A:1857–1863.
   PubMed Web of Science ®Google Scholar
• BOSHER JM, WILLIAMS T, HURST HC: The developmentally-regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary-carcinoma. Proc. Natl. Acad. Sci. USA (1995) 92:744–747.
   PubMed Web of Science ®Google Scholar
• HOLLYWOOD DP, HURST HC: Targeting gene transcrip- tion - a new strategy to down-regulate c-erbB-2 expres-sion in mammary-carcinoma. Br. J. Cancer (1995) 71:753–757.
   PubMed Web of Science ®Google Scholar
• NOONBERG SB, SCOTT GK, HUNT A, HOGAN ME, BENZ CC: Inhibition of transcription factor binding to the HERZ promoter by triplex-forming oligonucleotides. Gene (1994) 149:123–126.
   PubMed Web of Science ®Google Scholar
• SHIVDASANI RA, ORKIN SH: The transcriptional control of hematopoiesis. Blood (1996) 87:4025–4039.
   PubMed Web of Science ®Google Scholar
• LOOK AT: Oncogenic transcription factors in the human acute leukemias. Science (1997) 278:1059–1064.
   PubMed Web of Science ®Google Scholar
• GUBERNATOR K, BOHM HJ: Rational design of bioactive molecules. In: Structure-Based Ligand Design. Gubernator K, Balm HJ (Eds.), Wiley-VCH, Weinheim, Germany (1998):1–13.
   Google Scholar
• CREIGHTON TE: Interactions with other molecules. In:Proteins: Structures and Molecular Properties (2nd Edition). WH Freeman, New York, USA (1993):329–384.
   Google Scholar
• MURRE C, McCAW PS, BALTIMORE D: A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell (1989) 56:777–783.
   PubMed Web of Science ®Google Scholar
• LENARDO M, PIERCE JW, BALTIMORE D: Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility. Science (1987) 236:1573–1577.
   PubMed Web of Science ®Google Scholar
• GHOSH I, CHMIELEWSKI J: A 6-sheet peptide inhibitorof E47 dimerization and DNA binding. Chem. Biol. (1998) 5:439–445.
   PubMed Web of Science ®Google Scholar